In my postings in the "Maximize Reservatrol Thread", it was suggested that Transdermal Reservatrol may help maximize the effectiveness of RESV. I did some preliminary calculations based upon a research paper originally quoted by Niner, which allows one to make predictions of the Flux of various compounds based upon their molecular weight. Taking the MW of RESV, I suggested that the predicted effectiveness of Transdermal Resv would be very good.
Now, there is finally some research on topical and transdermal delivery of RESV. I haven't have a chance to read the entire paper yet, but I'm posting it here.
Despite good partitioning into the SC, the permeability of highly lipophilic
molecules is always low. This is probably due to the accumulation of lipophilic drugs
in the SC. This phenomenon was not observed with non-ionic resveratrol, which
showed higher permeability via the skin. These results support the superiority of
resveratrol for both topical and transdermal delivery. Resveratrol transport via the skin
was closely related to the vehicle in which it was formulated, with aqueous buffers
with lower pH values exhibiting good permeability/deposition. The viable
epidermis/dermis but not the SC layer acted as a diffusion barrier for resveratrol
permeation. Piceatannol, a more-hydrophilic analogue of resveratrol, showed lower
permeation compared to resveratrol. Resveratrol delivery by skin route may avoid the
degradation because the low metabolism in the skin, resulting in the possible
prolongation of half-life and sufficient concentration in the systemic circulation.
Moreover, resveratrol retained within the skin after topical application can be an
efficient way to be a therapy or prevention of UV exposure and skin carcinogenesis.
Further study is, of course, needed to confirm these efficiencies. This study indicates
the promise of further in vivo and clinical applications of resveratrol delivery via the
skin.
Based upon the new research, I'm curious about what you guys think?
Edited by Smithy, 19 April 2008 - 01:26 AM.